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OBJECTIVE — Ketosis-prone diabetes (KPD) is an emerging syndrome that encompasses
several distinct phenotypic subgroups that share a predisposition to diabetic ketoacidosis. We
investigated whether the A subgroup of KPD, characterized by complete insulin depen-
dence,absent-cellfunctionalreserve,lackofisletcellautoantibodies,andstrongfamilyhistory
of type 2 diabetes, represents a monogenic form of diabetes.
RESEARCH DESIGN AND METHODS — Over 8 years, 37 patients with an A
phenotype were identiﬁed in our longitudinally followed cohort of KPD patients. Seven genes,
including hepatocyte nuclear factor 4A (HNF4A), glucokinase (GCK), HNF1A, pancreas duode-
nal homeobox 1 (PDX1), HNF1B, neurogenic differentiation 1 (NEUROD1), and PAX4, were
directly sequenced in all patients. Selected gene regions were also sequenced in healthy, unre-
lated ethnically matched control subjects, consisting of 84 African American, 96 Caucasian, and
95 Hispanic subjects.
RESULTS — The majority (70%) of the A KPD patients had no signiﬁcant causal poly-
morphisms in either the proximal promoter or coding regions of the seven genes. The combi-
nation of six potentially signiﬁcant low-frequency, heterozygous sequence variants in HNF-1
(A174V or G574S), PDX1 (putative 5–untranslated region CCAAT box, P33T, or P239Q), or
PAX4(R133W)werefoundin27%(10/37)ofpatients,withoneadditionalpatientrevealingtwo
variants, PDX1 P33T and PAX4 R133W. The A174V variant has not been previously reported.
CONCLUSIONS — Despite its well-circumscribed, robust, and distinctive phenotype of
severe, nonautoimmune-mediated -cell dysfunction, A KPD is most likely not a predom-
inantlymonogenicdiabeticsyndrome.SeveralAKPDpatientshavelow-frequencyvariants
in HNF1A, PDX1,o rPAX4 genes, which may be of functional signiﬁcance in their
pathophysiology.
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T
ype 1 and type 2 diabetes are com-
plex, heterogeneous diseases with
genetic and environmental compo-
nents contributing to their pathophysiol-
ogy, clinical progression, and severity.
Although rapid technological advances in
genotyping, such as high-throughput,
large-scale, whole-genome approaches,
have identiﬁed a number of genetic vari-
ants linked to both types of diabetes, ma-
jor genetic contributions have been
conﬁrmed in relatively small subsets of
patients. A signiﬁcant obstacle to identi-
fyinggeneticlocithatcontributetodiabe-
tes is the phenotypic heterogeneity of the
disease (1). The lack of speciﬁcity in the
current classiﬁcation of diabetes and in
clinical criteria that deﬁne their “types”
has impeded the ability of investigators to
circumscribe this diverse illness with suf-
ﬁcientprecisioninordertomakeaccurate
genotype-phenotype correlations.
We and others have identiﬁed and
prospectively characterized an emerging
syndrome that does not ﬁt the current
American Diabetes Association (ADA)
classiﬁcationoftype1andtype2diabetes
(rev.in2).Termedketosis-pronediabetes
(KPD), this syndrome is characterized by
patients who present with diabetic keto-
acidosis (DKA), which unequivocally de-
ﬁnes the illness and clearly reﬂects severe
-cell dysfunction as an etiologic factor.
Our group has prospectively tested and
rigorously validated a classiﬁcation
scheme for KPD that is based on the pres-
ence or absence of -cell autoantibodies
(A or A) and the presence or absence
of -cell functional reserve ( or )
(3,4). This A system deﬁnes KPD pa-
tients with high accuracy, distinguishes
four phenotypic subgroups, and strongly
predicts the natural history of each sub-
groupwithregardtoglycemiccontrol,in-
sulin dependence, and -cell functional
reserve (4).
A KPD comprises a unique and
phenotypically distinct group of patients
whohaverelativelyearly-onsetdiabetesand
permanent, severe -cell dysfunction but
lackevidencefor-cellautoimmunity.Spe-
ciﬁcally, they lack circulating autoantibod-
ies to GAD65 or tyrosine phosphatase–
like protein (insulinoma-associated
protein-2, or IA-2) that are typical of pa-
tients with autoimmune type 1 diabetes.
Furthermore, the frequencies of class II
HLA alleles known to confer susceptibil-
itytoautoimmunetype1diabetesaresig-
niﬁcantly lower in this subgroup of KPD
patients than in the autoimmune-
mediated A KPD subgroup (3,5). In
our cohort, patients with A KPD
also have a high frequency (85%) of
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often in multiple generations (3). We hy-
pothesizedthatAKPDpatientshave
a high likelihood of possessing sequence
variants in one or more genes associated
with -cell development or regulation of
insulin secretion.
Mutations in a number of genes asso-
ciated with both -cell development and
regulation of insulin secretion have been
identiﬁed as causes of -cell dysfunction
resulting in diabetes. Maturity-onset dia-
betes of the young (MODY) is a clinically
heterogeneous group of diabetic syn-
dromescharacterizedbyinsulinsecretory
defects, childhood or adolescent onset,
and an autosomal dominant inheritance
pattern of the disease (6). The six known
MODY syndromes (MODY 1 though
MODY 6) result from mutations in the
following genes: hepatocyte nuclear fac-
tor 4A (HNF4A), encoding HNF-4; glu-
cokinase (GCK); HNF1A, encoding HNF-
1; pancreas duodenal homeobox 1
(PDX1), also known as IPF1, IDX1,o r
STF1; HNF1B, encoding HNF-1; and
neurogenicdifferentiation1(NEUROD1),
also known as -2 (2), respectively. A
homozygous variant, R133W, in the
PAX4 gene has also been associated with
severe -cell dysfunction in KPD patients
of West-African descent (7), likely repre-
senting the A subgroup of KPD.
HNF-4, HNF-1, PDX1, HNF-1,
NEUROD1, and PAX4 form a network of
transcriptionfactorsinthe-cellthatreg-
ulates the expression of insulin as well as
additional genes involved in glucose
transport and metabolism and mitochon-
drialmetabolism(8).Theclinicalfeatures
of the different MODY syndromes vary
with the speciﬁc genetic etiologies (9).
Here,wesetouttoexamineandchar-
acterize genetic variation in minimal pro-
moter, ﬂanking intronic, and exonic
regions of HNF4A, GCK, HNF1A, PDX1,
HNF1B, NEUROD1, and PAX4 in our
A KPD patients. We found no sig-
niﬁcant causal mutation in either the
proximal promoter or coding regions of
the six MODY or PAX4 genes, which
could be associated with the distinctive
diabeticphenotypeinthemajorityofKPD
patients. This ﬁnding suggests that
A KPD is predominantly a nonmo-
nogenic diabetic syndrome. Numerous
sequence variants were found with an av-
erage frequency of 1 in 244 base pairs
(bp), and 40% of these were low-
frequency variants (i.e., minor allele fre-
quency [MAF] 5%). Comparison of
allelefrequencieswithethnicallymatched
control subjects obtained from the Baylor
Polymorphism Resource (BPR) identiﬁed
several low-frequency variants within
HNF1A, PDX1, and PAX4, the occurrence
of which was greater than ﬁvefold higher
in our A KPD patient group.
RESEARCH DESIGN AND
METHODS— This study was ap-
proved by the institutional review boards
for genetic studies of KPD patients at Bay-
lor College of Medicine and the Harris
County Hospital District, Houston,
Texas, and informed consent was ob-
tained from all subjects. Adult patients
admitted to Ben Taub General Hospital
with DKA were identiﬁed at the time of
their hospital stay, recruited to the study,
and followed prospectively thereafter as
outpatients in a dedicated research clinic
between July 1999 and February 2006.
DKA was deﬁned by the presence of all of
the following: anion gap 15, blood pH
7.30, serum bicarbonate 17 mmol/l,
serum glucose 200 mg/dl, serum ke-
tones 5.2 mmol/l, and urine ketones
13.9 mmol/l. KPD patients were classi-
ﬁed as A or A based on the presence
or absence of GAD65 or IA-2 autoanti-
bodies, measured in sera by quantitative
radioligand binding assays with recent
modiﬁcations. As described in Maldo-
nado et al. (3), patients were classiﬁed as
A if the autoantibody index for at least
one of the autoantibodies exceeded the
ethnic-speciﬁc 99th percentile or A if
the index for all antibodies tested were
below the 99th percentile. Patients were
classiﬁed as  or  based on the pres-
enceorabsenceof-cellfunctionalreserve,
measured by fasting serum C-peptide con-
centrationandC-peptideresponsetogluca-
gon within 1 week after resolution of
ketoacidosis and follow-up visits at 6 and
12 months (3). Only patients with the
A phenotype of KPD (n 	 37) were
investigated in this study.
Control group
Genomic DNA samples were obtained
from established lymphoblast cell lines
from the BPR collection. Healthy adults,
recruited in Houston, Texas, were com-
prised of three, self-declared ethnic
groups (African American, Caucasian,
and Hispanic). Blood samples were as-
signed an alphanumeric code, and all
identifyinginformationwasremoved.For
this study, PCR and direct DNA sequenc-
ing were performed on selected regions
from 84 African American, 96 Caucasian,
and 95 Hispanic DNA samples.
Molecular biology
Complete experimental procedures
used in this work are available in the
online appendix (available at http://
care.diabetesjournals.org/cgi/content/
full/dc08-1529/DC1), including Tables
A1–A4.
RESULTS— The clinical, immuno-
logic, and biochemical features of 37 un-
related A KPD patients in this study
were found to be similar to those de-
scribedintheoriginalphenotypiccharac-
terizationofthissyndrome(3).Theywere
46% Hispanic, 38% African American,
and 16% Caucasian and had relatively
early-onset diabetes (mean age at diagno-
sis 27.8 
 12.7 years), with a slight male
predominant sex ratio of 1.6 to 1. The
patients were lean (mean BMI 23.5 
 2.7
kg/m
2), with a high frequency of family
history of type 2 diabetes in ﬁrst-degree
relatives (84%). Noncompliance with in-
sulin treatment was the primary reason
fortheindexpresentationwithDKA,with
only 14% of patients presenting with
new-onset diabetes at the time of the in-
dex episode of DKA. Indexes of -cell se-
cretory function (fasting C-peptide,
glucagon stimulation test using area un-
der the curve of C-peptide, and ho-
meostasis model assessment 2 of -cell
function) showed low -cell functional
reserve,bothatthetimeoftheinitialDKA
episode and on subsequent follow-up af-
ter 12 months. The patients were insulin
sensitive as measured by the homeostasis
model assessment 2 of insulin resistance
index. Their glycemic control was poor at
baseline and improved (without attaining
ADA goals) after 12 months of treatment
with insulin (Table 1). None of the
A KPD patients were able to discon-
tinue insulin therapy without promptly
developing ketosis.
The proximal promoter, exons, and
ﬂankingintronicregionsofHNF4A,GCK,
HNF1A, PDX1, HNF1B, NEUROD1, and
PAX4 were characterized by DNA se-
quencing of PCR amplicons for the 37
A KPD patients. The seven genes,
totaling 24 kilobase pairs (kb), resulted
in the identiﬁcation of 99 sequence vari-
ants for the A KPD patients (see on-
lineappendixTablesA2aandA2b).Forty
percent (40 of 99) of the identiﬁed vari-
ants had a MAF of 5% (see online ap-
pendix Table A3). The distribution of
sequence variants observed in the in-
tronic and untranslated regions (UTRs)
was approximately four- to sevenfold
higher than that for the proximal pro-
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pendix Table A4). The average frequency
of sequence variants found in the seven
gene regions was 1 in 244 bp.
To focus on sequence variants that
might play a functional role in the patho-
physiology of severe -cell failure in
A KPD, we selected those that had
an MAF of 10% in at least one of the
ethnic groups and resulted in a change in
an amino acid residue or a sequence vari-
ant in either a known DNA binding ele-
ment or within the proximal promoter
region(Table2).Sevenmissensevariants,
one CCAAT box variant, and one proxi-
mal promoter variant were identiﬁed and
further studied. They were HNF-1
A174V; HNF-1 G574S; PDX1 P33T;
PDX1 P239Q; GCK A11T; HNF-1
N228K; PAX4 R133W; PDX1 (18
C3T), which we term a putative 5-UTR
CCAATboxvariant;andHNF-4P2pro-
moter. Several of these variants have been
associatedwithMODYsyndromes,type2
diabetes, or KPD, including HNF-1
G574S (10–12), PDX1 P33T (13), PDX1
P239Q(14),andPAX4R133W(7),while
HNF-1 A174V, HNF-1 N228K, and
the HNF4A P2 promoter variants appear
novel to this study.
PCR amplicons containing these vari-
ants were sequenced in ethnically
matched control subjects from the BPR
collection to assess allele frequencies
within ethnic groups. The allele frequen-
cies for GCK A11T, HNF-1 N228K, and
HNF4A P2 promoter variants showed
only a modest increase to no difference in
A KPD case subjects compared with
thatoftheethnicallymatchedBPRcontrol
subjects. Six variants, however, in either
HNF-1 (i.e., A174V or G574S), PDX1
(i.e., putative 5-UTR CCAAT box, P33T,
or P239Q), or PAX4 R133W showed a
ﬁvefold or higher allele frequency differ-
ence in the A KPD group compared
with that of ethnically matched control
subjects (Table 2). Although the small
number of A KPD patients in this
analysis made statistical comparisons un-
reliable despite the apparent difference in
allele frequencies, several observations
suggest possible etiological roles for these
sixvariants.HNF-1G574Sandputative
PDX1 5-UTR CCAAT box variants were
found in both Hispanic and African
American A KPD patient groups,
and the PAX4 R133W variant was found
in both Caucasian and African American
Table 1—Clinical characteristics of A KPD patients
n 37
Demographic
Age (years) 36.7 
 12.8
Age at diagnosis of diabetes (years) 27.8 
 12.7
Duration of diabetes (years)* 6.5 
 8.7
BMI (kg/m
2) 23.5 
 2.7
Male:female 1.63:1
First-degree relative with diabetes (%) 83.8
Glycemic indices
A1C at index DKA (%) 14.4 
 2.5
A1C at 12 months (%) 11.4 
 2.1
-Cell function indices
Fasting C-peptide at baseline (ng/ml) 0.28 
 0.28
Fasting C-peptide at 12 months (ng/ml) 0.11 
 0.1
GST-AUC C-peptide at baseline (ng/ml) 3.26 
 3.2
GST-AUC C-peptide at 6 months (ng/ml) 0.9 
 0
HOMA2-% at baseline 5.7 
 4.8
HOMA2-% at 12 months 6.5 
 13.7
Insulin therapy discontinued at 12 months 0
Insulin sensitivity
HOMA2-IR at baseline 0.27 
 0.29
HOMA2-IR at 12 months 0.17 
 0.19
Precipitant of index DKA (%)
Noncompliance 67.6
New onset without clear precipitant 13.5
Acute illness 18.9
Dataareareexpressedasmean
SDforcontinuousvariablesandpercentageforcategoricalvariables.*Five
patients had new-onset diabetes diagnosed at the time of presentation with the index DKA. GST area under
the curve (AUC) was calculated using the trapezoidal method. HOMA-IR and HOMA2-%B were calculated
using a computer program available at http://www.dtu.ox.ac.uk/.
Table 2—Sequence variants enriched in A  KPD patients
Exon Patient ID Variant dbSNP KPD BPR Fold difference
HIS group
HNF4AP2 KPD0115 50bp 5’; G3C 2.9% (1/34) 2.6% (5/190) 1.1
HNF1Ex2 KPD0203 A174V; C3T 2.9% (1/34) 0.0% (0/190) 5.6
HNF1Ex9 KPD0110 G574S; G3A rs1169305 2.9% (1/34) 0.5% (1/190) 5.6
HNF1Ex3 KPD0006 N228K; C3G 2.9% (1/34) 3.2% (6/190) 0.9
PDX1Ex1 KPD0216 CCAAT; C3T 2.9% (1/34) 0.5% (1/190) 5.6
AFA group
GCKEx1a KPD0123 A11T; G3A 3.8% (1/26) 1.8% (3/168) 2.2
HNF1Ex9 KPD0102; KPD0119 G574S; G3A rs1169305 7.1% (2/28) 1.2% (2/168) 6.0
PDX1Ex1 KPD0069; KPD0123 CCAAT; C3T 7.1% (2/28) 1.2% (2/168) 6.0
PAX4Ex3 KPD0014; KPD0208 R133W; C3T rs2233578 7.1% (2/28) 4.2% (7/168) 1.7
CAU group
PDX1Ex1 KPD0193 P33T; C3A 8.3% (1/12) 0.0% (0/192) 15.8
PDX1Ex2 KPD0053 P239Q; C3A 8.3% (1/12) 0.5% (1/190) 15.8
PAX4Ex3 KPD0193 R133W; C3T rs2233578 8.3% (1/12) 0.0% (0/192) 15.8
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nor the PDX1 P33T variants were found
in their respective ethnic control groups,
nor was the PAX4 R133W variant found
in the Caucasian BPR group.
CONCLUSIONS — In this study, we
completely sequenced and analyzed
seven genes for variants that might be
causative for a monogenic pathophysiol-
ogyinKPDpatientswiththecarefullycir-
cumscribed A phenotype of severe,
relatively early-onset, nonimmunologic
-cellfailureandpronenesstoketoacido-
sis.Wefoundnosigniﬁcantevidencefora
role of HNF4A, GCK, HNF1A, PDX1,
HNF1B, NEUROD1, and PAX4 mutations
in the majority of the A KPD pa-
tients. Hence, A KPD as a whole is
unlikely to represent a monogenic syn-
drome, despite the high frequency of a
family history of type 2 diabetes (85%)
inmultiplegenerationsanditsstronglink
to -cell dysfunction. Several potentially
signiﬁcant genetic variants, however,
were identiﬁed within either HNF1A,
PDX1, and/or PAX4 that in aggregate rep-
resented30%ofcasesubjects.Thesevari-
ants were located within or near the
functional domains of the HNF-1,
PDX1, and PAX4 proteins or a regulatory
region of the PDX1 gene. In vitro studies
(7,12–14) suggest that some of the previ-
ouslyreportedmutantvariantsreducethe
production of insulin. Hence, further
study of these variants, including their
functional effects and the inheritance pat-
terns in the families of the affected pa-
tients, are warranted and underway.
Two variants, HNF-1 G574S and
the PDX1 putative 5-UTR CCAAT box,
were identiﬁed in both African American
and Hispanic A KPD patients. Sev-
eral studies have identiﬁed the HNF-1
G574S variant exclusively in African
American (10,15) or African populations
(11,16). HNF-1 G574S has been associ-
ated with “atypical” diabetes in African
American (10) and African (11) popula-
tions, although this association was not
conﬁrmed in other studies (15,16). Re-
cently, Navalo ´n-García et al. found the
HNF-1 G574S variant in two unrelated
Mexican type 2 diabetic patients with
end-stage renal disease who had no
known African ancestry but not in 66 un-
related,nondiabeticMexicancontrolsub-
jects (12). Cockburn et al. (17) identiﬁed
the 18 C3T variant in the PDX1 gene,
referred to here as a putative 5-UTR
CCAAT box, in one type 2 diabetic pa-
tient designated as having mixed African
andEastIndianancestry.Thisvariantwas
not found in either 60 unrelated nondia-
betic Indo-Trinidadian or 60 unrelated
nondiabetic Afro-Trinidadian subjects
(17). Here, the 5-UTR CCAAT promoter
sequence variant was found downstream
of the putative initiation start site in three
A KPD patients. This places the
CCAAT box within the 5-UTR of the
PDX1 gene; such downstream boxes have
been shown to be a functional, regulatory
elements (18). The relevance of the re-
cently evolved 5-UTR CCAAT box in
PDX1 is unknown, although the presence
of multiple enhancers in the proximal
promoterregionand5-UTRiscongruent
with the central role of PDX1 in the regu-
lation of -cell development and insulin
secretion. Studies are underway to inves-
tigate the role of sequence variation
within the putative 5-UTR CCAAT box
and its effect on PDX1 gene expression.
Our ﬁndings that both HNF-1 G574S
and the PDX1 putative 5-UTR CCAAT
box variants were identiﬁed in African
American and Hispanic A KPD pa-
tients provides direct evidence that these
low-frequency variants may not be re-
stricted to speciﬁc ethnic groups.
Mauvais-Jarvis et al. (7) reported an
association of the homozygous PAX4
W133 variant with KPD in West-African
patients. They demonstrated that gluca-
gon-stimulated insulin secretion was
markedlylowerinfourpatientswhowere
homozygous for the mutant allele com-
pared with those who were heterozygous
(n 	 11) or homozygous (n 	 18) for the
wild-type allele. Based on our A classiﬁ-
cation system (3,4), we would assign this
West-African cohort to the subgroup of
A KPD, rather than the subgroup of
A KPD whom we investigated in the
present study. A KPD patients are
distinct from A KPD patients, being
predominantly lean with early-onset of
diabetesandlackingany-cellfunctional
reserve. As a group, A KPD patients
show no recovery of insulin secretory re-
sponse to glucagon following the index
DKA, hence it is not possible for us to
ascertain whether presence of the PAX4
R133W variant is speciﬁcally associated
with markedly reduced -cell function.
Similar to the Mauvais-Jarvis et al. (7)
study (n 	 200), we did not ﬁnd the
W133 variant in any of our 96 Caucasian
BPR control subjects. We did, however,
ﬁndoneCaucasianAKPDpatientas
heterozygous for the R133W variant. The
differencesinKPDsubgroupsmakeitdif-
ﬁcult to suggest that the PAX4 R133W
variant is either pathogenetically signiﬁ-
cant or ethnically restricted in patients
with the A phenotype of KPD.
The remaining three variants, how-
ever, were found in speciﬁc ethnic
groups. The HNF-1 A174V variant,
which has not been reported previously,
was found in one Hispanic A KPD
patient. The A174V variant is located
withintheB-domain,whichconfersDNA
binding sequence speciﬁcity for HNF-1
(19). Encoded variation within the B-
domain could impair the ability of
HNF-1 to properly bind and regulate
downstream target genes. Family-based
studies,whichcoulddeterminetheroleof
this variant in KPD, could not be per-
formed given that both parents are de-
ceased. Both PDX1 coding variants were
found individually in two unrelated Cau-
casian A KPD patients. The PDX1
P33T variant has been associated with
type 2 diabetes and increased susceptibil-
ity to gestational diabetes (13), while
PDX1 P239Q has been identiﬁed in two
families with early-onset type 2 disease
(14).
Recently, Murphy et al. (9) proposed
a classiﬁcation scheme for monogenic di-
abetes resulting from mutations that
cause -cell dysfunction, a scheme that is
based on speciﬁc genetic diagnoses and
points to speciﬁc therapeutic interven-
tions. Among these monogenic syn-
dromes, the most common genetic
mutations among individuals with famil-
ial, young-onset diabetes (without ex-
trapancreatic features) are in the HNF1A
gene. Here, we identiﬁed only two low-
frequency variants in the HNF1A gene in
an otherwise well-deﬁned KPD cohort
with early, complete, nonautoimmune
-cell dysfunction. While it is plausible
that KPD is a monogenic syndrome and
we incorrectly chose its corresponding
gene(s) to sequence, it is more likely that
A KPD is a complex genetic syn-
drome. Thus, this study highlights the
difﬁcultyintraditionalcandidategeneap-
proaches using conventional sequencing
methods.Thesearchforgeneticetiologies
ofKPDmaynotcomefromtheanalysisof
a handful of candidate genes but rather a
more comprehensive and systematic ap-
proach. This could be accomplished by
expanding the set to hundreds of genes
involving numerous pathways such as
metabolicandproliferativenetworks(20)
that capture the KPD phenotype by using
next-generation sequencing technologies
(21). Work is underway to explore this
approach.
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